ACW positive XanaMIA Interim Analysis outcome
Filed with ASX · · 3 pages · English
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Trading Halt
- Actinogen secures $4.3m of non-dilutive R&D tax funding
- Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial
- ACW XanaMIA trial fully enrolled with 246th participant
- ACW positive XanaMIA Data Monitoring Committee meeting
Later from Actinogen Medical
- Continuation of Trading Halt
- ACW December 2025 quarterly activity report & Appendix 4C
- ACW secures funding beyond XanaMIA AD trial final results
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW receives further $1.9m FY2025 R&D rebate from ATO
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical